Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antiviral
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection. Methods: A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12). Results: In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ2=3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup. Conclusions: In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.
Abstract
Background/Aims: Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection. Methods: A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12). Results: In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ2=3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup. Conclusions: In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.
참고문헌 (32)
- Mendizabal M, "Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories", J Viral Hepat, 24, pp.442~453 (2017)[DOI]
- "Recommendations for testing, managing, and treating hepatitis C"[URL]
- European Association for the Study of the Liver, "EASL Recommendations on Treatment of Hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)[DOI]
- Mucke MM, "Special populations: treating hepatitis C in patients with decompensated cirrhosis and", or advanced renal impairment, 2017, pp.37(Suppl 1), 19~25
- Nazario HE, "Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml", min, 2016, pp.36, 798~801
- Bhamidimarri KR, "Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease", J Hepatol, 63, pp.763~765 (2015)[DOI]
- Hundemer GL, "Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency", Infect Dis (Lond), 47, pp.924~929 (2015)[DOI]
- Saxena V, "Safety and efficacy of sofosbuvir-containing regimens in hepatitis Cinfected patients with impaired renal function", Liver Int, 36, pp.807~816 (2016)[DOI]
- Levin A, "Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease", Kidney Int Suppl, 3, pp.1~150 (2013)[DOI]
- Firu SG, "Neutrophil Gelatinase Associated Lipocalin (NGAL)-a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof?", J Med Life, (8 Spec), pp.15~20 (2015)
- Tsuchimoto A, "Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients", PLoS One, 9, pp.e110527~ (2014)[DOI]
- Elia C, "Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study", J Hepatol, 63, pp.593~600 (2015)[DOI]
- Strazzulla A, "Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?", World J Hepatol, 8, pp.815~824 (2016)[DOI]
- Coppolino G, "The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists", J Nephrol, 28, pp.393~402 (2015)[DOI]
- Cianfrone P, "How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study", J Nephrol, 30, pp.95~102 (2017)[DOI]
- Ziol M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C", Hepatology, 41, pp.48~54 (2005)[DOI]
- Vallet-Pichard A, "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)[DOI]
- Lin ZH, "Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis", Hepatology, 53, pp.726~736 (2011)[DOI]
- Itenov TS, "Serum and plasma neutrophil gelatinase associated lipocalin (NGAL) levels are not equivalent in patients admitted to intensive care", J Clin Lab Anal, 28, pp.163~167 (2014)[DOI]
- Castillo-Rodriguez E, "Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease", Nephron, 136, pp.263~267 (2017)[DOI]
- Holzscheiter L, "NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction", Clin Chem Lab Med, 52, pp.537~546 (2014)
- Bolignano D, "Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function", Kidney Blood Press Res, 31, pp.274~279 (2008)[DOI]
- Moledina DG, "Performance of serum creatinine and kidney injury biomarkers for diagnosing histologic acute tubular injury", Am J Kidney Dis, 70, pp.807~816 (2017)[DOI]
- Choudhary NS, "Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis", Indian J Gastroenterol, 36, pp.113~116 (2017)[DOI]
- Li T, "Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis", Liver Int, 37, pp.974~981 (2017)[DOI]
- Grubb A, "Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check", Scand J Clin Lab Invest, 70, pp.65~70 (2010)[DOI]
- Ralib AM, "Dynamic changes of plasma neutrophil gelatinase-associated lipocalin predicted mortality in critically ill patients with systemic inflammatory response syndrome", Indian J Crit Care Med, 21, pp.23~29 (2017)[DOI]
- Choi JW, "Elevated plasma neutrophil gelatinase-associated lipocalin level as a risk factor for anemia in patients with systemic inflammation", Biomed Res Int, 2016, pp.9195219~ (2016)
- Sansonno D, "Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection", Clin Exp Immunol, 140, pp.498~506 (2005)[DOI]
- Goossens N, "Hepatitis C virus-induced hepatocellular carcinoma", Clin Mol Hepatol, 21, pp.105~114 (2015)[DOI]
- Villani R, "DAAs rapidly reduce inflammation but increase serum VEGF Level: a rationale for tumor risk during anti-HCV treatment", PloS One, 11, pp.e0167934~ (2016)[DOI]
- Carrier P, "Anti-hepatitis C virus drugs and kidney", World J Hepatol, 8, pp.1343~1353 (2016)[DOI]